PLA2R1 and autoimmune disease: MN is now recognized as a renal-limited autoimmune disease, with antibodies against PLA2R (aPLA2Rab) detected in 70% to 80% of cases and antibodies against thrombospondin type-1 domain-containing 7A (THSD7A) in 2% to 5% of patients (86) (87),.